Campa goes global: Reliance Consumer launches soft drink brand in Nepal, partners with Chaudhary Group for local rollout
According to a joint statement issued on Monday, RCPL has partnered with Nepal's largest conglomerate, Chaudhary Group (CG), to manufacture and distribute the Campa product range locally. 'The launch marks RCPL's entry in Nepal and further reaffirms the company's long-term commitment to the country,' the companies said.
Chaudhary Group will support RCPL in local production and distribution across Nepal to ensure smooth supply chain operations.
The initial Campa product portfolio will include Campa Cola, Campa Lemon, Campa Orange, Campa Energy Gold Boost, and Campa Energy Berry Kick, PTI reported.
Campa, which was acquired by Reliance in 2022 and reintroduced in the Indian market in 2023, is emerging as a strong challenger in the Indian soft drinks industry. In addition to India and now Nepal, RCPL has also launched Campa in key Middle East markets including the UAE, Oman and Bahrain.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Here's The Average Price of a 6-Hour Gutter Upgrade in Marietta
Homebuddy.com
Read More
Undo
RCPL Executive Director Ketan Mody said, 'We are investing for the long term and see great potential for accelerated growth in the region. We are delighted to come together with our esteemed partner today to transform the beverage experience for consumers across Nepal.'
Chaudhary Group, which operates over 200 companies and manages 260 brands worldwide, is best known for Wai Wai noodles—a popular brand sold in India and other countries.
The group has business interests across food and beverages, financial services, education, infrastructure, automobiles, IT, real estate, and hospitality.
'We are confident that Campa will resonate strongly with local consumers who appreciate distinctive beverage options,' said Nirvana Chaudhary, Managing Director of Chaudhary Group, quoted PTI. 'This strategic alliance not only expands our beverage portfolio but also reinforces our position as a key player in the region's competitive beverage market.'
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
24 minutes ago
- Time of India
IFFCO MD Dr. US Awasthi On India's Cooperative Push And How It's Empowering Farmers
Dr. Uday Shankar Awasthi, Managing Director of IFFCO and renowned as the "Fertiliser Man of India," shares his experiences working with nine Indian Prime Ministers. He highlights contributions from leaders like Rajiv Gandhi, who initiated computerisation, and H.D. Deve Gowda's focus on farmers. Dr. Awasthi also shares his experience with current Prime Minister Narendra Modi. Under Dr. Awasthi's leadership, IFFCO has risen to global prominence. Watch Read More
Time of India
25 minutes ago
- Time of India
India, US talks for proposed trade pact going on at a very fast pace: Piyush Goyal
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The negotiations between India and the US for a proposed trade agreement are going at a fast pace, Commerce and Industry Minister Piyush Goyal said on Indian team has reached Washington for the next round of talks on the first tranche of the bilateral trade agreement."Negotiations are going on at a very fast pace and in the spirit of mutual cooperation so that we can come out with a win-win trade complementing agreement with the United States," Goyal told reporters Commerce Secretary Sunil Barthwal at a separate event said that negotiations for proposed trade agreements with the European Union (EU) and the US are going said that the free trade agreements (FTAs) that India is doing are one of the key enablers to promote global capability centres (GCCs) in the country."So if you look at the free trade agreements today, which we are doing with the UK, which we have just announced, with European Union (EU), which is going on, with the US again discussions are on with several other countries in the world," Barthwal said here at CII GCC Business Summit and the US are negotiating a bilateral trade agreement (BTA). They are targeting to conclude the first phase of the pact by fall (September-October) of this India and the EU are also negotiating an June 2022, India and the 27-nation EU bloc resumed negotiations for a comprehensive free trade agreement, an investment protection agreement and a pact on geographical indications (GIs) after a gap of over eight talks stalled in 2013 due to differences over the level of opening up of the markets. India and the EU are targeting to conclude the free trade deal by the end of this the secretary said that today's agreements are different from the traditional FTAs, which were confined to traditional trade, tariffs and manufacturing. The new pacts are a more complex set of agreements which include services, a regulatory system in services, including the FDI (foreign direct investment)."Those are being looked at (in the new pacts)," he said, adding that now there is also an institutional mechanism in these pacts to look at issues like harmonising regulations and these are important facets of GCCs, he said, adding that modern FTAs will lead to the innovation corridor, which will facilitate GCCs in India "We are looking at the IPR (intellectual property rights) chapters. We are looking at what the coordination mechanism will be in case disputes arise. That is another area which we look at in FTAs," the secretary the new age pacts focus on principles of digital trade, which the partner countries have to adopt."If there is a data localisation or data privacy laws, then how will they be looked at. That is another angle, which we define in these FTAs," he new trade agreements, Barthwal said, are addressing a whole gamut of issues. "And therefore, it is taking a lot of time when we do these FTAs. There are detailed discussions, detailed deliberations, and detailed stakeholder consultation," he added that in the FTA with the UK, there is a chapter on innovation, which was not the case earlier. There is also a mechanism to set up innovation working groups under that deal, which was announced on May 6, but has not yet been signed."The ultimate point of these FTAs is that once these are (businesses) will get certainty about those regulations, because those regulations are not going to change unless and until you have agreed differently. And it gives certainty," Barthwal said.
Mint
28 minutes ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
